Search research articles
Contact Us
Filters
Showing results (61-70 of 68) with videos related to
Page
of 7
Sort By:
You have reached the last page of results.
This site can display upto 68 results.
Contact Dermatitis
|
April 3, 2009
Chromated metal products may be hazardous to patients with chromate allergy
Johannes Geier, Holger Lessmann, Brigitte Hellweg, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 8, 2025
Brentuximab Vedotin Combination for Relapsed Diffuse Large B-Cell Lymphoma
Nancy L Bartlett, Uwe Hahn, Won-Seog Kim, et al.
Haematologica
|
February 2, 2017
Early treatment intensification with R-ICE and 90Y-ibritumomab tiuxetan (Zevalin)-BEAM stem cell transplantation in patients with high-risk diffuse large B-cell lymphoma patients and positive interim PET after 4 cycles of R-CHOP-14
Mark Hertzberg, Maher K Gandhi, Judith Trotman, et al.
Blood
|
December 29, 2025
Brentuximab Vedotin and Nivolumab in Combination With Chemotherapy for Nonbulky, Early-Stage Classical Hodgkin Lymphoma
Jeremy S Abramson, David J Straus, Nancy L Bartlett, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 4, 2017
Idarubicin Dose Escalation During Consolidation Therapy for Adult Acute Myeloid Leukemia
Kenneth F Bradstock, Emma Link, Juliana Di Iulio, et al.
Blood Cancer Journal
|
March 27, 2024
How comparable are patient outcomes in the "real-world" with populations studied in pivotal AML trials?
Ing Soo Tiong, Meaghan Wall, Ashish Bajel, et al.
Blood
|
August 30, 2023
Sorafenib plus intensive chemotherapy in newly diagnosed FLT3-ITD AML: a randomized, placebo-controlled study by the ALLG
Sun Loo, Andrew W Roberts, Natasha S Anstee, et al.
American Journal of Hematology
|
January 3, 2023
Targeting MCL-1 and BCL-2 with polatuzumab vedotin and venetoclax overcomes treatment resistance in R/R non-Hodgkin lymphoma: Results from preclinical models and a Phase Ib study
Elisabeth A Lasater, Dhara N Amin, Rajat Bannerji, et al.
Page
of 7
Search research articles
Search
Showing results (61-70 of 68) with videos related to
Sort By:
Page
of 7
You have reached the last page of results.
This site can display upto 68 results.
Contact Dermatitis
|
April 3, 2009
Chromated metal products may be hazardous to patients with chromate allergy
Johannes Geier, Holger Lessmann, Brigitte Hellweg, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 8, 2025
Brentuximab Vedotin Combination for Relapsed Diffuse Large B-Cell Lymphoma
Nancy L Bartlett, Uwe Hahn, Won-Seog Kim, et al.
Haematologica
|
February 2, 2017
Early treatment intensification with R-ICE and 90Y-ibritumomab tiuxetan (Zevalin)-BEAM stem cell transplantation in patients with high-risk diffuse large B-cell lymphoma patients and positive interim PET after 4 cycles of R-CHOP-14
Mark Hertzberg, Maher K Gandhi, Judith Trotman, et al.
Blood
|
December 29, 2025
Brentuximab Vedotin and Nivolumab in Combination With Chemotherapy for Nonbulky, Early-Stage Classical Hodgkin Lymphoma
Jeremy S Abramson, David J Straus, Nancy L Bartlett, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 4, 2017
Idarubicin Dose Escalation During Consolidation Therapy for Adult Acute Myeloid Leukemia
Kenneth F Bradstock, Emma Link, Juliana Di Iulio, et al.
Blood Cancer Journal
|
March 27, 2024
How comparable are patient outcomes in the "real-world" with populations studied in pivotal AML trials?
Ing Soo Tiong, Meaghan Wall, Ashish Bajel, et al.
Blood
|
August 30, 2023
Sorafenib plus intensive chemotherapy in newly diagnosed FLT3-ITD AML: a randomized, placebo-controlled study by the ALLG
Sun Loo, Andrew W Roberts, Natasha S Anstee, et al.
American Journal of Hematology
|
January 3, 2023
Targeting MCL-1 and BCL-2 with polatuzumab vedotin and venetoclax overcomes treatment resistance in R/R non-Hodgkin lymphoma: Results from preclinical models and a Phase Ib study
Elisabeth A Lasater, Dhara N Amin, Rajat Bannerji, et al.
Page
of 7